[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2024, "totalPay": 1057225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 60, "title": "Senior VP & Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Supriya  Roth Ph.D.", "title": "Head of Commercial Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shui  He Ph.D.", "title": "Head of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hongwei  Wang M.D., Ph.D.", "title": "Head of ADC Development & Clinical Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marsha  Crochiere Ph.D.", "title": "Head of Translational Medicine & Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 10, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.32, "open": 1.29, "dayLow": 1.29, "dayHigh": 1.43, "regularMarketPreviousClose": 1.32, "regularMarketOpen": 1.29, "regularMarketDayLow": 1.29, "regularMarketDayHigh": 1.43, "payoutRatio": 0.0, "beta": 1.131, "forwardPE": -1.1260504, "volume": 1327574, "regularMarketVolume": 1327574, "averageVolume": 536432, "averageVolume10days": 663010, "averageDailyVolume10Day": 663010, "bid": 1.3, "ask": 1.37, "bidSize": 1, "askSize": 1, "marketCap": 83104256, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.39, "priceToSalesTrailing12Months": 29.469595, "fiftyDayAverage": 1.1637, "twoHundredDayAverage": 1.4726, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 13622301, "profitMargins": 0.0, "floatShares": 41180042, "sharesOutstanding": 62018100, "sharesShort": 4695721, "sharesShortPriorMonth": 5064919, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0758, "heldPercentInsiders": 0.23386, "heldPercentInstitutions": 0.33738, "shortRatio": 11.28, "shortPercentOfFloat": 0.091800004, "impliedSharesOutstanding": 62018100, "bookValue": 1.413, "priceToBook": 0.9483369, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -96286000, "trailingEps": -1.59, "forwardEps": -1.19, "enterpriseToRevenue": 4.831, "enterpriseToEbitda": -0.169, "52WeekChange": -0.648294, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 1.34, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.2, "targetMedianPrice": 6.0, "recommendationMean": 1.57143, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 88944000, "totalCashPerShare": 1.434, "ebitda": -80537000, "totalDebt": 19462000, "quickRatio": 5.201, "currentRatio": 5.654, "totalRevenue": 2820000, "debtToEquity": 22.206, "revenuePerShare": 0.046, "returnOnAssets": -0.31252, "returnOnEquity": -0.74804, "grossProfits": 2820000, "freeCashflow": -42194624, "operatingCashflow": -73753000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -6.76099, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1633699800000, "postMarketChangePercent": 1.4850719, "postMarketPrice": 1.3599, "postMarketChange": 0.019899964, "regularMarketChange": 0.02, "regularMarketDayRange": "1.29 - 1.43", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 536432, "fiftyTwoWeekLowChange": 0.507, "fiftyTwoWeekLowChangePercent": 0.6086435, "fiftyTwoWeekRange": "0.833 - 5.39", "fiftyTwoWeekHighChange": -4.0499997, "fiftyTwoWeekHighChangePercent": -0.7513914, "fiftyTwoWeekChangePercent": -64.8294, "shortName": "Pyxis Oncology, Inc.", "longName": "Pyxis Oncology, Inc.", "earningsTimestampStart": 1762891200, "earningsTimestampEnd": 1762891200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.59, "epsForward": -1.19, "epsCurrentYear": -1.30333, "priceEpsCurrentYear": -1.0281357, "fiftyDayAverageChange": 0.17630005, "fiftyDayAverageChangePercent": 0.15149957, "twoHundredDayAverageChange": -0.13259995, "twoHundredDayAverageChangePercent": -0.09004479, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "averageAnalystRating": "1.6 - Buy", "corporateActions": [], "postMarketTime": 1755905892, "regularMarketTime": 1755892801, "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.51515, "regularMarketPrice": 1.34, "marketState": "CLOSED", "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]